Program
Anti-CD39 Antibody/TGF-beta RII Ectodomain Fusion Protein ES014
Its studies are mostly in Desmoid Tumors · Neoplasm Metastasis, led by 2 companies.
Drug pageAnti-CD39 Antibody/TGF-beta RII Ectodomain Fusion Protein ES014: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Elpiscience (Suzhou) Biopharmaits history only | 22 open or running | phase 2since Mar 31, 2026 | Jan 28, 2023 | Feb 28, 2027phase 1 · NCT05717348 |
| Elpiscience Biopharmaits history only | 10 open or running | phase 1since May 11, 2022 | May 11, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 11, 2022First study: phase 1 study in Advanced Solid TumorNew to Elpiscience BiopharmaElpiscience Biopharma · NCT05381935
- Jan 28, 2023Elpiscience (Suzhou) Biopharma’s first study: phase 1 study in Neoplasm MetastasisNew to Elpiscience (Suzhou) BiopharmaElpiscience (Suzhou) Biopharma · NCT05717348 · 120 enrolled · China
- Mar 31, 2026Phase 2 study in Desmoid TumorsPhase 2 reachedElpiscience (Suzhou) Biopharma · NCT07541430 · 50 planned · China
Ahead
- Feb 28, 2027Primary completion: phase 1 study in Neoplasm MetastasisElpiscience (Suzhou) Biopharma · NCT05717348
- Jan 2028Primary completion: phase 2 study in Desmoid TumorsElpiscience (Suzhou) Biopharma · NCT07541430
TargetBeta
“A fusion protein composed of a monoclonal antibody directed against the cell surface receptor CD39 (cluster of differentiation 39; ectonucleoside triphosphate diphosphohydrolase-1; NTPDase1; ENTPD1) and ”NCIt, by rule
Other programs on ENTPD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-CD39 Monoclonal Antibody IPH5201 | innate-pharma | phase 2 | 2 |
| Anti-PD-1/Anti-CD39 Bispecific Antibody BNT317rule | BioNTech | phase 2 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07541430Desmoid Tumors · China | 2 | Recruiting | Elpiscience (Suzhou) Biopharma | Jan 2028 | 50 |
| NCT05717348Neoplasm Metastasis · China | 1 | Active, not recruiting | Elpiscience (Suzhou) Biopharma | Feb 28, 2027 | 120 |
| NCT05381935Advanced Solid Tumor | 1 | Withdrawn | Elpiscience Biopharma | Apr 30, 2026 | 0 |
How it is read
Names in the registry
- “ES014”, 5 entries
Conditions, from the studies’ own filings
- Desmoid Tumors, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.